ANI PHARMACEUTICALS INC 8K

ANI Pharmaceuticals appointed Henry Gosebruch to its Board of Directors effective August 19, 2026, and announced the immediate resignation from the Board of Muthusamy (Samy) Shanmugam, who will remain in his executive roles.

ANI Pharmaceuticals, Inc. announced that it has appointed Henry Gosebruch, an experienced biopharmaceutical executive and current CEO of Lakefront Biotherapeutics NV, to its Board of Directors effective August 19, 2026, to support the company’s strategic transformation into a leading rare disease company, while Muthusamy (Samy) Shanmugam has resigned from the Board effective immediately but will continue in his executive roles as Head of Research and Development and Chief Operating Officer of New Jersey Operations.

Filing Facts

CIK

1023024

Ticker

ANIP

Form

8K

Source Type

fda

Accession

0001023024-26-000071

Alert Tier

5